Log in to your Inderes Free account to see all free content on this page.
Active Biotech
0.112
SEK
-2.1 %
ACTI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.1%
-62.73%
-36.02%
-50.28%
-45.76%
-44.86%
-76.85%
-83.83%
-97.86%
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Read moreMarket cap
137.53M SEK
Turnover
551.09K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.2.
2025
Annual report '24
8.5.
2025
Interim report Q1'25
ShowingAll content types
Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech’s website
Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio